DCC-3009 for GIST
Trial Summary
What is the purpose of this trial?
The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.
Will I have to stop taking my current medications?
The trial requires that you have not received any systemic anticancer therapy or radiotherapy within 14 days before starting the study drug. It does not specify about other medications, so you should discuss your current medications with the trial team.
Research Team
Clinical Team
Principal Investigator
Deciphera Pharmaceuticals, LLC
Eligibility Criteria
This trial is for people with advanced or metastatic GIST who've had a previous treatment fail. They should have a life expectancy over 3 months, at least one measurable tumor, be relatively active (ECOG PS of 0 or 1), and have good organ and bone marrow function.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive DCC-3009 in 28-day cycles, including Part 1 (Dose Escalation) and Part 2 (Dose Expansion)
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- DCC-3009
Find a Clinic Near You
Who Is Running the Clinical Trial?
Deciphera Pharmaceuticals, LLC
Lead Sponsor